A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Trial Profile

A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs MHAA 4549A (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 03 Oct 2017 The study has been discontinued in Czech Republic.
    • 17 Sep 2017 The study has been discontinued in Bulgaria.
    • 08 Sep 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top